Abstract Over the past decade, vitamin D has generated considerable interest as potentially having important effects on the vasculature and the kidney. Animal and human data indicate that vitamin D suppresses the activity of the reninangiotensin system and improves endothelial function. Observational studies in humans suggest that low 25-hydroxyvitamin D (25[OH]D) levels are associated with a higher risk of hypertension. However, findings from randomized trials of vitamin D supplementation (with cholecalciferol or ergocalciferol) to lower blood pressure are inconsistent, possibly stemming from variability in study population, sample size, vitamin D dose, and duration. Supplementation with activated vitamin D (i.e., 1,25-dihydroxyvitamin D or analogues) in patients with chronic kidney disease reduces urine albumin excretion, an important biomarker for future decline in renal function. These studies are reviewed, with special emphasis on recent findings. Definitive studies are warranted to elucidate the effects of vitamin D supplementation on mechanisms of hypertension and kidney disease.
Introduction
Vitamin D has long been known to be an important factor for normal calcium metabolism and skeletal health. In the past decade, resurging interest and new research have implicated vitamin D deficiency as a potential contributor to the pathophysiology of many extraskeletal conditions, including vascular diseases such as high blood pressure and kidney disease [1] . Recent experimental animal studies and observational human studies have repeatedly suggested that supplementation with vitamin D metabolites may lower the risk for hypertension and kidney injury, but definitive human trials favoring the adoption of vitamin D therapy for the primary or secondary prevention of these conditions are still pending.
One of the many challenges in evaluating the biologic role of vitamin D in influencing blood pressure and renal function is deciphering which circulating vitamin D metabolites to measure in cross-sectional studies (i. Another challenge is designing an investigation to elucidate the potential mechanisms whereby vitamin D could impact blood pressure and kidney function. To date, the most intensely investigated mechanism of action by which vitamin D could prevent or improve vascular diseases is the proposed negative regulation of the renin-angiotensin system (RAS). However, several other biologic pathways were implicated by prior studies.
The following discussion reviews mechanistic studies that have led to human investigations, evaluates the human data with a specific focus on the limitations of their conclusions, and proposes future directions that may definitively ascertain the role of vitamin D in the pathophysiology of hypertension and kidney disease.
Vitamin D and Hypertension

Mechanisms of Association
The association of vitamin D with blood pressure and hypertension has been described for over a quarter of a century [2] . The most notable mechanism implicating vitamin D with hypertension is its role as a negative regulator of the RAS [3] ; inappropriately elevated RAS activity is known to contribute to human hypertension and cardiovascular risk [4] [5] [6] .
The development of VDR null mice has facilitated numerous experiments that have shed light on the relationship between vitamin D, the RAS, and hypertension [7] . Li et al. reported that VDR null mice had significant elevations in renin activity and circulating plasma angiotensin II concentrations [3] and exhibited increased activity of the local cardiac-tissue RAS [3, 8] . These mice displayed a phenotype of hypertension and cardiac hypertrophy that was attenuated when RAS antagonists were administered. A distinct mouse model of 1-alpha-hydroxylase deficiency also exhibited a phenotype of enhanced RAS activity, hypertension, and cardiac hypertrophy, which was attenuated by treatment with 1,25(OH) 2 D or RAS antagonists [9] . The findings of these experiments were further consolidated with the demonstration that 1,25(OH) 2 Other vascular-protective pathways also have been implicated in the association of vitamin D with hypertension.
In vitro experiments have shown that vitamin D reduces the deleterious effect of advanced glycation products on the endothelium, improves activity of the nitric oxide system, reduces inflammatory parameters, and enhances prostacyclin production [20] [21] [22] [23] . In conjunction with these basic findings, human studies exploring mechanisms of vitamin D in the pathophysiology of hypertension reported that concentrations of vitamin D metabolites were associated with improved endothelial function and oxidative stress [24-28] as well as circulating concentrations of adipocytokines implicated in blood pressure control [29] [30] [31] [32] [33] .
Summary of Human Clinical Data
Most human clinical studies evaluating the role of vitamin D on blood pressure have been cross-sectional analyses. The majority of these were consistent with the animal data in showing an inverse association between vitamin D and blood pressure [34] [35] [36] or the prevalence of hypertension [37, 38] . In contrast, at least two large cross-sectional studies demonstrated no detectable association between vitamin D and blood pressure or the prevalence of hypertension, but in addition to the traditional limitations of cross-sectional analyses, these results may be biased by the fact that the study populations had relatively high 25(OH)D concentrations and prevalent use of antihypertensive drugs, both of which could obscure a potential association [39, 40] .
Prospective studies have produced similarly mixed results. In a longitudinal analysis of men from the Health Professionals' Follow-Up Study and women from the Nurses' Health Study followed for 4 to 8 years, Forman et al. observed a pooled adjusted relative risk for incident hypertension of 3.18 (95% CI, 1.39-7.29) when comparing individuals with lower (<15 ng/mL) versus higher (≥30 ng/mL) concentrations of 25(OH)D [41] . In a subsequent nested case-control analysis of normotensive women from the Nurses' Health Study II, they observed an adjusted odds ratio for incident hypertension of 1.66 (P-trend 0.01) when comparing those with 25(OH)D levels in the lowest quartile versus the highest quartile [42] . The longitudinal Michigan Bone Health and Metabolism Study evaluated the risk for systolic hypertension in over 500 Caucasian women who had 25(OH)D and blood pressure assessments in 1993 and again 14 years later, in 2007 [43] . Although they observed no cross-sectional association between 25(OH)D concentrations and concurrent blood pressure at baseline in 1993, 25 (OH)D concentrations lower than 32 ng/mL at baseline were associated with a significantly increased risk for systolic hypertension in 2007 (adjusted OR, 3.0; 95% CI, 1.01-8.7). In contrast, Jorde et al. reported conflicting observations from the Tromso study, which followed individuals naïve to antihypertensive therapy from 1994 to 2008 [44] . They did note an inverse association between systolic blood pressure and quartiles of 25(OH)D at baseline in 1994, but these baseline 25(OH)D concentrations did not predict incident hypertension or future blood pressure. Regardless of whether the disparity in these findings was due to the narrow range of 25(OH)D concentrations within the study populations or other, unrecognized confounders, it underscored the need for definitive interventional studies.
Observational studies have suggested higher blood pressures in winter months and at latitudes further from the equator, thus implicating insufficient ultraviolet radiation exposure and decreased cutaneous synthesis of vitamin D 3 as potential culprits in vascular disease [45] . Interventional studies to evaluate the effect of cutaneous vitamin D 3 synthesis with ultraviolet radiation exposure have produced interesting but mixed results. Krause et al. randomized 18 hypertensive subjects to receive total body ultraviolet radiation with either UVA or UVB and observed that those receiving UVB had significant increases in 25(OH)D concentrations with concomitant decrements in 24-hour ambulatory systolic and diastolic blood pressures (−6 mm Hg) [46] . In a similar randomized study design, Scragg et al. evaluated 119 normotensive individuals but observed no changes in blood pressure despite significant rises in 25 (OH)D concentrations [47] . The findings of these studies may be limited by their relatively small sample sizes, short durations of follow-up (6 and 12 weeks, respectively), and focus on distinct hypertensive or normotensive study populations.
To date, more than 10 interventional studies have evaluated the effect of oral vitamin D therapy on blood pressure, although a minority of these trials were designed specifically to evaluate blood pressure effects [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . Most demonstrated no effect of oral vitamin D supplementation on blood pressure or incident hypertension. The largest of these studies was the Women's Health Initiative (N036,282), designed to evaluate fracture and cancer risk in a population of largely 25(OH)Dinsufficient women receiving either a small dose of vitamin D 3 (400 IU/day) with calcium supplementation, or placebo [55] . After 7 years of follow-up, no changes in blood pressure or incident hypertension were observed. The interpretation of these results was limited by the fact that the dose of vitamin D 3 was modest and was not expected to significantly raise 25 (OH)D levels [62] [63] [64] . In addition, the rate of medication noncompliance was high (about 40%), and about 60% of women in the placebo group also received supplemental vitamin D during the course of the study. The second largest of these randomized studies (N0438), designed to evaluate the effect of vitamin D 3 supplementation on weight loss, included overweight and obese individuals and did not exclude the use of antihypertensive medications [60] . No changes in blood pressure were observed after 1 year of therapy with either a placebo or vitamin D 3 at a dosage of 40,000 IU/ week or 20,000 IU/week. Because 25(OH)D levels in this study rose from approximately 20 ng/mL to higher than 50 ng/mL in the 40,000 IU/week group, these data argued that reasonable elevations in 25(OH)D did not influence blood pressure. On the other hand, it is debatable whether a 1-year follow-up was sufficient to detect blood pressure outcomes, or whether a largely obese population with heterogeneous use of antihypertensive medications was the ideal study population.
Only two randomized trials to date have been designed to evaluate blood pressure as the primary end point in a population maintained free of antihypertensive therapy [50, 51] . The first showed that, when compared with placebo, a single dose of vitamin D 3 100,000 IU in a 25(OH)D deficient population (N 0189) did not lower blood pressure after 5 weeks [50] . The conclusions of this study are limited by its short duration of follow-up, relatively small sample size, and the modest 7 ng/mL rise in 25(OH)D levels (from a baseline of 13 ng/mL), all of which may have hampered the detection of a potential effect. In the second study, elderly 25(OH)D-deficient women who received vitamin D 3 800 IU/day for 8 weeks exhibited a small but significant decline in systolic blood pressure (−7 mm Hg) when compared with those who received placebo [51] . Again, the conclusions of this positive study were limited by its short duration of follow-up, small sample size (N 0148), and modest effect size.
Given the lack of well-designed, large-scale intervention studies evaluating the influence of oral vitamin D supplementation on blood pressure, several meta-analyses have attempted to aggregate prior study findings but have produced inconclusive results [65, 66• 
Future Directions
To date, in vitro and animal experiments have provided convincing evidence to speculate the involvement of vitamin D in the pathophysiology of hypertension, possibly via its influence on the RAS, but human studies have not consistently supported this hypothesis. Because most human clinical data stem from cross-sectional or interventional studies with notable design limitations, there is a need for definitive, large-scale randomized controlled trials. To detect whether a true association exists between vitamin D and blood pressure control, future interventional studies ideally should be designed with sufficient sample size, long duration of follow-up, higher vitamin D supplementation doses, and restriction of antihypertensive drug use, and potentially should control for confounders of the RAS such as dietary sodium intake.
The Vitamin D and Omega-3 Trial (VITAL) study (NCT01169259) is a large, randomized controlled trial (N020,000) in the United States that opened for recruitment in late 2010 and aims to evaluate the impact of higher-dose vitamin D 3 supplementation (2,000 IU/day) on cardiovascular and cancer outcomes over 5 years. The size, duration of follow-up, and higher doses in this study design may allow sufficient power to examine the effect of long-term oral vitamin D 3 supplementation on blood pressure. In addition, a subset of about 1,000 randomized participants in this trial will also have 24-hour ambulatory blood pressure assessments at baseline and after 2 years of study. This ongoing trial does have some potential limitations: (1) Participants will be older (>50 years of age), and therefore many may already have significant subclinical vascular disease that may not readily respond to a mild therapy; (2) the main trial of 20,000 participants may include patients taking antihypertensive drugs (including those that may influence the RAS), although the 1,000 participants who undergo 24-hour ambulatory blood pressure monitoring will not be taking antihypertensive medication; (3) the placebo group will be allowed to take up to 800 IU/day of vitamin D 3 to reflect current standards of care [69] , which could potentially attenuate the difference in effect between the intervention and control groups; and (4) whether an intervention that moderately raises concentrations of 25(OH)D (as opposed to direct treatment with a VDR agonist) can provide therapeutic benefit over 5 years is unclear.
Vitamin D and Kidney Disease
Mechanisms of Association
A history of hypertension is frequent in those who develop kidney disease, yet vitamin D has been implicated as being renoprotective independent of its potential effects on blood pressure. This discussion focuses on the novel independent effects that vitamin D metabolites may have on pathways that affect renal function and consequently the progression of kidney disease.
As in the case of blood pressure, the most prominent mechanism explaining the role of vitamin D in kidney disease has been its negative regulation of the RAS in animal models. In addition to elevations in circulating RAS components, VDR-null mice also display increased expression of renal-vascular renin mRNA [3] , supporting experiments that suggest that vitamin D may be an inhibitor of renin gene expression [11] . When subjected to a model of renal injury consisting of unilateral ureteral obstruction, these animals demonstrated more severe kidney injury and fibrosis in the obstructed kidney, when compared with wildtype mice [70] . The administration of an angiotensinreceptor antagonist attenuated the observed injury, suggesting that the deficiency of signaling through the VDR resulted in unfavorably high intrarenal RAS activity and obstructive renal injury. Similarly, mice that are deficient in the activity of the 1-alpha-hydroxylase enzyme have exhibited increased activity of the intrarenal RAS that can be ameliorated with 1,25(OH) 2 D treatment [9] . When mice with diet-induced obesity were treated with doxercalciferol (1-alpha-hydroxyvitamin D 2 ), the expression of intrarenal renin and angiotensin II type 1 receptors was decreased, with concurrent decrements in proteinuria, podocyte injury, mesangial expansion, and inflammation [71] .
Nearly identical renoprotective effects of vitamin D signaling were shown in three studies using mouse models of diabetes (streptozocin-induced [type 1 diabetes] and db/db or KK-A y /Ta [type 2 diabetes]); these animals develop proteinuria and renal injury with elevated intrarenal RAS activity [72] [73] [74] . Given alone, a VDR agonist (1, 25 [OH] 2 D or paricalcitol) decreased RAS activity in these mice and attenuated the proteinuria and kidney injury. This effect was reproduced with angiotensin-receptor blocker therapy, but there was a synergistic effect on decreasing RAS activity and preventing further kidney injury when both the VDR agonist and angiotensin-receptor blocker were used in combination [72] [73] [74] . These experiments further support the RAS as a key mediator of the renal influence of VDR agonism, but they implicated the involvement of two other pathways. VDR agonist treatment was also observed to inhibit the transforming growth factor beta (TGF-β) [72] and extracellular signal-regulated protein kinase (p-ERK1/ 2) [74] systems in these animals, suggesting a potential antiproliferative or antiinflammatory renoprotective function of VDR agonism in addition to its negative regulation of the RAS.
To date, the only corollary human mechanistic study showed that higher 25(OH)D concentrations were associated with significantly lower renal-vascular RAS activity in normotensive individuals with normal kidney function [75•] . Although this study was cross-sectional in nature, the results strongly support the mechanism of vitamin Dinduced RAS inhibition in humans because it controlled for major modulators of the RAS: dietary sodium was fixed and no antihypertensive medications were included. The Modifiable Effectors of Renin System Activation: Treatment Evaluation (MODERATE) study (NCT01320722), currently enrolling subjects in the United States, will further characterize the biologic relationship between vitamin D supplementation and the renal-vascular RAS in humans by evaluating renal-vascular RAS activity and renal plasma flow before and after randomization to 8 weeks of oral vitamin D 2 50,000 IU/week, or placebo. Future studies are still needed to evaluate the mechanism of VDR agonists on the RAS, inflammatory pathways, and proteinuria in diabetes.
Summary of Human Clinical Data
Most human clinical studies in this area have investigated the role of vitamin D in patients with established chronic kidney disease (CKD) of varying stages, a condition usually marked by 1,25(OH) 2 D insufficiency or deficiency, elevated parathyroid hormone levels, and often concurrent hypertension, diabetes, or both. Observational studies have shown cross-sectional associations between lower 25(OH)D concentrations and the prevalence of CKD and proteinuria [76] [77] [78] . In an analysis of more than 15,000 individuals in the Third National Health and Nutrition Examination Survey (NHANES III), for example, de Boer et al. observed that those in the lowest quartile compared with the highest quartile of 25(OH)D levels had an adjusted OR for prevalent albuminuria of 1.37 (P<0.01) [78] . Ravani et al. observed an inverse and independent longitudinal relationship between 25(OH)D concentrations and the 2-year progression of kidney disease in 168 individuals with non-dialysis-dependent CKD (stages 2-5) [79] . Other studies have reached similar conclusions [80, 81] .
High-quality, prospective observational and interventional studies evaluating the role of vitamin D 2 or D 3 in kidney disease are sparse. Kim et al. recently showed that, in patients with diabetes and CKD already treated with conventional RAS antagonists, vitamin D 3 supplementation reduced albuminuria and TGF-β, supporting similar observations in diabetic mice treated with paricalcitol [82] . A meta-analysis of 22 studies of low to moderate quality (17 observational and 5 randomized trials) suggested that vitamin D 2 or D 3 supplementation did not significantly affect serum creatinine or urine albumin excretion, even though supplementation was sufficient to raise 25(OH)D levels and suppress parathyroid hormone [83] . However, most of the studies included in this aggregate analysis were not designed to evaluate outcomes of disease progression, and because CKD is a state of relative 1-alpha-hydroxylase insufficiency, the effectiveness of vitamin D 2 or D 3 supplementation on any outcome is unclear.
In contrast to investigations that have evaluated the influence of vitamin D 2 or D 3 in kidney disease, those that have studied the effect of direct VDR agonism have shown more conclusive and consistent findings. To date, there have been at least five notable interventional studies evaluating the renoprotective benefits of VDR agonist therapy in patients with CKD [84] [85] [86] [87] 88 •] ( Table 1) . These five studies have provided human clinical evidence to support the aforementioned animal data demonstrating a reduction in surrogate biochemical measures of renal failure (such as proteinuria) [72] [73] [74] , but they were not designed to examine whether VDR agonist therapy delayed the progression of CKD or whether it may have a role in the primary prevention of kidney disease. Agarwal et al. synthesized the results of 220 patients from three randomized placebo-controlled studies who had CKD (stages 3 or 4) treated with paricalcitol or placebo for up to 6 months [84] . Paricalcitol therapy reduced automated dipstick proteinuria in 50% of the patients (P<0.01), whereas proteinuria was reduced in only 25% of those who received placebo. Although this study took into account the use of specific anti-RAS hypertensive medications, it may have been limited by the quantification of proteinuria via an [85] . Evaluating only 10 patients with IgA nephropathy who had proteinuria despite using RAS antagonist pharmacotherapy, Szeto et al. observed a 25% decrease in urine protein-tocreatinine ratio (P<0.01) within 6 weeks of receiving calcitriol 0.5 μg twice weekly [86] . Individuals who experienced lowering of proteinuria in this study also exhibited a proportional reduction in serum TGF-β, thus providing further support for vitamin D-induced inhibition of the TGF pathway [72] . In support of the Agarwal and Alborzi studies, Fishbane et al. also observed a 17% (P<0.05) reduction in proteinuria among 61 patients with CKD who were randomized to either paricalcitol or placebo for 6 months [87] . The largest and most recent interventional study by de Zeeuw et al. provides the strongest translation to date of animal to human evidence. In a multinational, double-blind placebo-controlled trial, de Zeeuw and colleagues randomly assigned 281 patients with type 2 diabetes with albuminuria, who were all on pharmacologic RAS antagonist therapy, to 6 months of placebo, paricalcitol 1 μg/day, or paricalcitol 2 μg/day [88•]. Patients treated with paricalcitol 2 μg/day experienced a steady 18-28% decrease in the urinary albumin-to-creatinine ratio when compared with placebo (the primary end point).
Future Directions
In parallel with studies in diabetic mice showing reductions in albuminuria and renal injury with combined VDR agonists and RAS-antagonist therapy [72] [73] [74] , the results by de Zeeuw et al. [88•] consolidate prior human data reported by Agarwal, Alborzi, Szeto, Fishbane et al. [84] [85] [86] [87] and strongly support the use of VDR agonists to reduce proteinuria in diabetic nephropathy that is already being treated with conventional RAS antagonism. Although these studies evaluated strong surrogate measures of progressive CKD (proteinuria), they have limitations: they did not evaluate long-term outcomes (such as the time to progression of disease or dialysis), and they were not designed to investigate whether the mechanism of the beneficial effects of VDR agonists was incremental RAS antagonism, synergistic inhibition of the TGF pathway, or other biologic mechanisms. A better understanding of these queries could have significant implications for the potential use of vitamin D analogues in the primary prevention of kidney disease, or for their continued use in CKD in combination with other pharmacotherapies. Furthermore, studies have associated the use of VDR agonists among non-dialysis-dependent and dialysis-dependent CKD patients with an improved survival benefit, but these studies were not designed to evaluate the underlying mechanism for improved survival [89] [90] [91] [92] [93] [94] . Future studies are needed to ascertain whether vitamin D therapy is effective for the primary prevention of CKD, to delay the progression of CKD stages, to reduce the need for dialysis in CKD, and to improve overall survival in CKD. Mechanistic studies in humans, to further identify the biologic pathways by which vitamin D influences renal function, may help to shape efficient trial designs.
Conclusions
Translational research has produced novel insights into the role of vitamin D in vascular diseases such as hypertension and kidney disease. The role of 1,25(OH) 2 D as a negative inhibitor of the RAS has been supported by mechanistic animal and human studies, but other potential biologic mechanisms to explain the role of vitamin D on vascular function are also emerging. To date, human clinical studies have ascribed a modest but inconsistent blood pressure lowering effect to oral vitamin D therapy and exposure to ultraviolet radiation. On the other hand, they have demonstrated a consistent decrement in surrogate measures of CKD progression, such as proteinuria, with VDR agonists. Future interventional studies with higher vitamin D doses, larger sample sizes, longer durations of follow-up, and study designs that are suited to measure and recognize the mechanism of action, may provide more conclusive data on whether vitamin D therapy may be beneficial in the primary prevention or the treatment of hypertension and kidney disease. 
